DE69617036T2 - Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung - Google Patents

Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung

Info

Publication number
DE69617036T2
DE69617036T2 DE69617036T DE69617036T DE69617036T2 DE 69617036 T2 DE69617036 T2 DE 69617036T2 DE 69617036 T DE69617036 T DE 69617036T DE 69617036 T DE69617036 T DE 69617036T DE 69617036 T2 DE69617036 T2 DE 69617036T2
Authority
DE
Germany
Prior art keywords
clavulanate
pharmaceutical formulation
formulation containing
containing amoxicillin
pediatric pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69617036T
Other languages
English (en)
Other versions
DE69617036D1 (de
Inventor
Joseph Burch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
GlaxoSmithKline LLC
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21705455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69617036(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline LLC, SmithKline Beecham Corp filed Critical GlaxoSmithKline LLC
Application granted granted Critical
Publication of DE69617036D1 publication Critical patent/DE69617036D1/de
Publication of DE69617036T2 publication Critical patent/DE69617036T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
DE69617036T 1995-09-07 1996-09-05 Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung Revoked DE69617036T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US335395P 1995-09-07 1995-09-07
PCT/US1996/014554 WO1997009042A1 (en) 1995-09-07 1996-09-05 Pharmaceutical formulation

Publications (2)

Publication Number Publication Date
DE69617036D1 DE69617036D1 (de) 2001-12-20
DE69617036T2 true DE69617036T2 (de) 2002-07-11

Family

ID=21705455

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69617036T Revoked DE69617036T2 (de) 1995-09-07 1996-09-05 Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung

Country Status (28)

Country Link
US (3) US6726908B2 (de)
EP (3) EP1093812A3 (de)
JP (1) JP3501289B2 (de)
KR (1) KR100495585B1 (de)
CN (1) CN1289084C (de)
AR (1) AR004510A1 (de)
AT (1) ATE208618T1 (de)
AU (1) AU711441B2 (de)
BR (1) BR9610396A (de)
CA (1) CA2231194C (de)
CO (1) CO4750658A1 (de)
CY (1) CY2359B1 (de)
CZ (1) CZ299595B6 (de)
DE (1) DE69617036T2 (de)
DK (1) DK0862431T3 (de)
ES (1) ES2165997T3 (de)
HK (2) HK1043042A1 (de)
HU (1) HUP9901437A3 (de)
IL (1) IL123563A (de)
NO (1) NO314831B1 (de)
NZ (3) NZ318282A (de)
PL (1) PL325411A1 (de)
PT (1) PT862431E (de)
SI (1) SI0862431T1 (de)
TR (1) TR199800415T1 (de)
TW (1) TW501926B (de)
WO (1) WO1997009042A1 (de)
ZA (1) ZA967546B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109503A1 (en) * 1995-06-06 2003-06-12 Smithkline Beecham P.L.C. Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
DE69617036T2 (de) * 1995-09-07 2002-07-11 Smithkline Beecham Corp Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung
GB9617780D0 (en) * 1996-08-24 1996-10-02 Smithkline Beecham Plc Method of treatment
US6294199B1 (en) 1999-04-13 2001-09-25 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising administering amoxycillin
CO5170471A1 (es) * 1999-04-13 2002-06-27 Beecham Pharmaceutical Pte Ltd Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
GB2365337A (en) * 1999-04-13 2002-02-20 Beecham Pharma Amoxycillin and potassium clavulanate high dosage regimen
US7250176B1 (en) * 1999-04-13 2007-07-31 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection
US6878386B1 (en) 1999-04-13 2005-04-12 Beecham Pharmaceuticals (Pte) Limited Method of treating a bacterial infection comprising amoxycillin and potassium clavulanate
AU5241200A (en) * 1999-06-29 2001-01-31 Miciopharma Chemical Aktiengesellschaft Retard formulation of amoxicillin for oral administration
US7838032B2 (en) 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US7985420B2 (en) 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US8012504B2 (en) 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6756057B2 (en) 2000-10-12 2004-06-29 Beecham Pharmaceuticals (Pte) Limited Amoxicillin and potassium clavulanate dosage form
EP1330236A2 (de) 2000-10-12 2003-07-30 Beecham Pharmaceuticals (Pte) Limited Amoxicillinhaltige arzneizusammensetzungen
PT1492511E (pt) 2002-04-09 2009-04-09 Flamel Tech Sa Formulação farmacêutica oral na forma de suspensão aquosa de microcápsulas para libertação modificada de princípio(s) activo(s)
KR100456833B1 (ko) * 2002-08-01 2004-11-10 주식회사 대웅 아목시실린 및 클라불라네이트를 함유하는 유핵정
US8614315B2 (en) 2009-12-25 2013-12-24 Mahmut Bilgic Cefdinir and cefixime formulations and uses thereof
TR200909787A2 (tr) 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Üçüncü kuşak bir sefalosporin ve klavulanik asit içeren farmasötik formülasyonlar.
TR201000688A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Aktif madde olarak sefaklor ve klavulanik asit içeren efervesan formülasyonlar.
TR201000686A1 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut Bakteriyel enfeksiyonların tedavisinde suda çözünebilir sefdinir ve klavulanik asit formülasyonları.@
TR201000687A1 (tr) 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Aktif madde olarak sefiksim ve klavulanik asit içeren efervesan formülasyonlar
WO2013057569A2 (en) 2011-10-19 2013-04-25 Micro Labs Limited Extended release pharmaceutical composition containing amoxicillin and clavulanic acid
MX2014008375A (es) * 2012-01-10 2017-07-27 Spector Michael Formulaciones pedriaticas de supspension oral de amoxicilina y clauvulanato de potasio y metodo para su uso.
WO2013173803A2 (en) * 2012-05-17 2013-11-21 Michael Spector Formulations of amoxicillin and clavulanate potassium and methods for using same
WO2013173808A2 (en) * 2012-05-17 2013-11-21 Michael Spector Methods for use of lower dose compositions of amoxicillin and clavulanate potassium and devices for use
US11278506B2 (en) 2015-10-09 2022-03-22 Rb Health (Us) Llc Pharmaceutical formulation

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) * 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
JO984B1 (en) * 1977-10-11 1979-12-01 بيتشام غروب ليمتد A dry pharmaceutical compound with a suitable dosage unit for oral administration
IL58461A0 (en) 1978-10-27 1980-01-31 Beecham Group Ltd Intramammary compositions comprising a clavulanic acid salt
NZ198241A (en) * 1980-09-27 1983-12-16 Beecham Group Ltd Tablet containing amoxycillin and potassium clavulanate
EP0080862B1 (de) * 1981-12-02 1985-09-25 Beecham Group Plc Pharmazeutische Zubereitung die Beta-Lactam Antibiotika enthält
US4673637A (en) 1984-04-23 1987-06-16 Hyman Edward S Method for detecting bacteria in urine and for treating rheumatoid arthritis, essential hypertension and other diseases associated with bacteriuria
DE3887179T2 (de) 1987-03-02 1994-06-16 Brocades Pharma Bv Pharmazeutische Zusammensetzung, pharmazeutisches Granulat und Verfahren zu ihrer Herstellung.
US5114929A (en) 1989-03-21 1992-05-19 Beecham Group P.L.C. Pharmaceutical formulation
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
KR910009271B1 (ko) 1989-06-20 1991-11-08 김영설 1,1-디옥소페닐실라노일 옥시메틸 D-6-[α-(메틸렌아미노)페닐-아세트아미도]-페니실라네이트와 그의 파라-톨루엔술폰산염
GB9007945D0 (en) * 1990-04-07 1990-06-06 Beecham Group Plc Pharmaceutical formulation
US5814337A (en) * 1992-10-07 1998-09-29 Beecham Group Plc Pharmaceutical formulation
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9114950D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Pharmaceutical formulation
AU5863894A (en) * 1993-01-22 1994-08-15 Smithkline Beecham Plc Pharmaceutical formulations comprising clavulanic acid alone or in combination with other beta-lactam antibiotics
GB9311030D0 (en) 1993-05-28 1993-07-14 Smithkline Beecham Corp Pharmaceutical formulations
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
GB9405856D0 (en) 1994-03-24 1994-05-11 Smithkline Beecham Plc Pharmaceutical formulation
GB9407386D0 (en) 1994-04-14 1994-06-08 Smithkline Beecham Plc Pharmaceutical formulation
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
ITMI941169A1 (it) 1994-06-06 1995-12-06 Smithkline Beecham Farma Formulazioni farmaceutiche
US5567439A (en) 1994-06-14 1996-10-22 Fuisz Technologies Ltd. Delivery of controlled-release systems(s)
GB9416599D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
GB9416600D0 (en) 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
DZ1926A1 (fr) 1994-09-03 2002-02-17 Smithkline Beckman P L C Formulations pharmaceutiques.
DZ2028A1 (fr) 1995-05-03 2002-10-23 Smithkline Beecham Plc Médicaments destinés au traitement d'infections bactériennes en pédiatrie.
US5830073A (en) 1995-07-28 1998-11-03 Voss; Brian C. Bowling lane surfaces
DE69617036T2 (de) * 1995-09-07 2002-07-11 Smithkline Beecham Corp Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung
EA002595B1 (ru) 1997-02-14 2002-06-27 Смитклайн Бичем Лаборатуар Фармасетик Фармацевтический препарат, содержащий амоксициллин и клавуланат, способ его приготовления и гранулят, содержащий амоксициллин и клавуланат
SE9700885D0 (sv) 1997-03-12 1997-03-12 Astra Ab New pharmaceutical formulation
KR20000076329A (ko) 1997-03-25 2000-12-26 다케다 야쿠힌 고교 가부시키가이샤 위장 점막 부착성 약제 조성물
GB9815532D0 (en) 1998-07-17 1998-09-16 Lek Pharmaceutical & Cvhemical Pharmaceutical suspension formulation
GB9818927D0 (en) 1998-08-28 1998-10-21 Smithkline Beecham Plc Pharmaceutical formulation
CO5170471A1 (es) * 1999-04-13 2002-06-27 Beecham Pharmaceutical Pte Ltd Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio

Also Published As

Publication number Publication date
EP1093812A2 (de) 2001-04-25
NZ337246A (en) 2000-07-28
TW501926B (en) 2002-09-11
EP0862431A1 (de) 1998-09-09
AU711441B2 (en) 1999-10-14
PL325411A1 (en) 1998-07-20
HK1015701A1 (en) 1999-10-22
CZ299595B6 (cs) 2008-09-17
NZ318282A (en) 2000-01-28
NO981008L (no) 1998-05-06
NZ337247A (en) 2001-05-25
CA2231194C (en) 2004-07-20
DK0862431T3 (da) 2002-03-11
JPH11512398A (ja) 1999-10-26
AU6973396A (en) 1997-03-27
TR199800415T1 (en) 1998-05-21
JP3501289B2 (ja) 2004-03-02
SI0862431T1 (en) 2002-06-30
HUP9901437A2 (hu) 1999-09-28
ZA967546B (en) 1998-03-06
DE69617036D1 (de) 2001-12-20
CN1289084C (zh) 2006-12-13
PT862431E (pt) 2002-04-29
EP0862431B1 (de) 2001-11-14
AR004510A1 (es) 1998-12-16
US20050261267A1 (en) 2005-11-24
NO314831B1 (no) 2003-06-02
US20010038838A1 (en) 2001-11-08
ES2165997T3 (es) 2002-04-01
HK1043042A1 (zh) 2002-09-06
NO981008D0 (no) 1998-03-06
CZ68398A3 (cs) 1998-07-15
ATE208618T1 (de) 2001-11-15
WO1997009042A1 (en) 1997-03-13
KR19990044495A (ko) 1999-06-25
CY2359B1 (en) 2004-06-04
EP0862431A4 (de) 1999-07-07
BR9610396A (pt) 1999-07-06
EP1147771A1 (de) 2001-10-24
HUP9901437A3 (en) 2000-03-28
EP1093812A3 (de) 2001-06-06
CA2231194A1 (en) 1997-03-13
MX9801903A (es) 1998-05-31
US20010043926A1 (en) 2001-11-22
KR100495585B1 (ko) 2005-09-09
US6726908B2 (en) 2004-04-27
CO4750658A1 (es) 1999-03-31
CN1200672A (zh) 1998-12-02
IL123563A (en) 2002-02-10

Similar Documents

Publication Publication Date Title
ATE208618T1 (de) Verwendung einer amoxicillin und clavulanat enthaltenden paediatrischen pharmazeutischen formulierung
DE69815833D1 (de) Amoxicillin und clavulanat enthaltende arzneizubereitungen
HK1050992A1 (zh) 含有藥物配方的阿莫西林和克拉維酸
NZ301231A (en) An optically active (+)-isomer of 2-piperidinylethoxy substituted 4-phenyl-2-benzopyran derivatives and medicaments
NO952357L (no) Formulering av insulinanaloger
AU609390B2 (en) Cyclodextrinclathrates of carbacycline derivatives and their use as medicinal drugs
PT1093815E (pt) Formulacao oral de 2-metil-tieno-benzodiazepina
FI953479A0 (fi) 1-aryylipyrimidiinijohdannaiset ja niiden farmaseuttinen käyttö
NO934547D0 (no) Oral behandling av Helicobacter-in-feksjon
CY2007001I2 (el) Φαρμακευτικο σκευασμα για χρηση στη θεραπεια του διαβητη
DE69320242D1 (de) Medizinische Selbstklebefolie und Arzneimittelzubereitung
BR9610983A (pt) Formas estáveis de administração farmacêuticas contendo paratormônio
BR9602915A (pt) Medicamentos uso e formulação farmacêutica
BR9608270A (pt) Composição compreendendo amoxicilina e acido clavulánico
BR9610821A (pt) Derivado de aminoácido uso de um composto e medicamento contendo o mesmo
DE69632533D1 (de) Intrapulmonare verabreichung vom hematopoietischem medikament
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
NO955258D0 (no) Medisinsk anvendelse av enzymer
ATE256465T1 (de) Orale arzneimittel zubereitung von piperdinoalkanole in gelöster form
AU7001796A (en) Benzoic acid compounds and medicinal use thereof
BR9610851A (pt) Composto processo de preparação de composto medicamento composição farmacêuticas e utilização do composto
NO307126B1 (no) Anvendelse av biologisk aktive ureidoderivater for fremstilling av et medikament for bruk i behandlingen av lentivirusindusert sykdom
AU5206793A (en) Use of CN-substituted benzimidazoles
FI950029A (fi) Uusia analgeettisia ja nootrooppisia lääkeaineita
KR960033538U (ko) 치과용 시린지의 착탈구조

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: SMITHKLINE BEECHAM P.L.C., BRENTFORD, MIDDLESEX, G

8331 Complete revocation